Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MYP006
MIFTS: 62

Myopia

Categories: Eye diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Myopia

About this section

MalaCards integrated aliases for Myopia:

Name: Myopia 12 77 26 38 30 56 6 45 15 41 74
Short-Sightedness 12 26
Near-Sightedness 12 26
Nearsightedness 26
Close Sighted 26
Short-Sighted 26
Near Vision 12
Nearsighted 26
Myopic 26

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:11830
KEGG 38 H02041
ICD9CM 36 367.1
MeSH 45 D009216
NCIt 51 C102533
SNOMED-CT 69 57190000
ICD10 34 H52.1
UMLS 74 C0027092
Sources

Summaries for Myopia

About this section
Genetics Home Reference : 26 Nearsightedness, also known as myopia, is an eye condition that causes blurry distance vision. People who are nearsighted have more trouble seeing things that are far away (such as when driving) than things that are close up (such as when reading or using a computer). If it is not treated with corrective lenses or surgery, nearsightedness can lead to squinting, eyestrain, headaches, and significant visual impairment.

MalaCards based summary : Myopia, also known as short-sightedness, is related to donnai-barrow syndrome and rare isolated myopia, and has symptoms including aniseikonia An important gene associated with Myopia is COL2A1 (Collagen Type II Alpha 1 Chain), and among its related pathways/superpathways are Degradation of the extracellular matrix and ECM-receptor interaction. The drugs Tropicamide and Atropine have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and testes, and related phenotypes are craniofacial and skeleton

Disease Ontology : 12 A refractive error characterized by the inability to see farther objects clearly.

Wikipedia : 77 Near-sightedness, also known as short-sightedness and myopia, is an eye disorder where light focuses in... more...

Sources

Related Diseases for Myopia

About this section

Diseases in the Myopia family:

Myopia 2, Autosomal Dominant Myopia 18, Autosomal Recessive
Myopia 3, Autosomal Dominant Myopia 17, Autosomal Dominant
Myopia 5, Autosomal Dominant Myopia 6
Myopia 7 Myopia 8
Myopia 9 Myopia 10
Myopia 11, Autosomal Dominant Myopia 12, Autosomal Dominant
Myopia 14 Myopia 16, Autosomal Dominant
Myopia 15, Autosomal Dominant Myopia 19, Autosomal Dominant
Myopia 20, Autosomal Dominant Myopia 21, Autosomal Dominant
Myopia 22, Autosomal Dominant Myopia 23, Autosomal Recessive
Myopia 24, Autosomal Dominant Myopia 25, Autosomal Dominant

Diseases related to Myopia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)
# Related Disease Score Top Affiliating Genes
1 donnai-barrow syndrome 33.5 COL11A1 COL18A1 COL2A1
2 rare isolated myopia 33.5 CHD7 COL2A1 FBN1 LRPAP1 P3H2 SCO2
3 marshall syndrome 33.1 COL11A1 COL2A1
4 refractive error 32.8 LRPAP1 PRIMPOL SCO2 SLC39A5 ZNF644
5 retinal detachment 31.9 COL11A1 COL18A1 COL2A1
6 kniest dysplasia 31.7 COL11A1 COL2A1
7 strabismus 31.2 COL11A1 COL2A1 TYR
8 lens subluxation 30.5 FBN1 P3H2
9 vitreous syneresis 30.4 COL11A1 COL2A1
10 microcornea, myopic chorioretinal atrophy, and telecanthus 12.6
11 deafness and myopia 12.5
12 myopia 6 12.4
13 degenerative myopia 12.4
14 myopia 12, autosomal dominant 12.3
15 myopia 13, x-linked 12.3
16 myopia 5, autosomal dominant 12.3
17 epiphyseal dysplasia, multiple, with myopia and conductive deafness 12.3
18 myopia 21, autosomal dominant 12.3
19 polydactyly, postaxial, with progressive myopia 12.3
20 myopia 2, autosomal dominant 12.3
21 myopia 1, x-linked 12.3
22 myopia 23, autosomal recessive 12.3
23 myopia 3, autosomal dominant 12.3
24 myopia, high, with cataract and vitreoretinal degeneration 12.3
25 myopia 22, autosomal dominant 12.3
26 myopia 24, autosomal dominant 12.3
27 myopia 17, autosomal dominant 12.3
28 myopia 26, x-linked, female-limited 12.3
29 myopia 18, autosomal recessive 12.2
30 myopia 11, autosomal dominant 12.2
31 myopia 16, autosomal dominant 12.2
32 myopia 15, autosomal dominant 12.2
33 myopia 19, autosomal dominant 12.2
34 joint laxity, short stature, and myopia 12.2
35 myopia 25, autosomal dominant 12.2
36 myopia 7 12.2
37 myopia 8 12.2
38 myopia 9 12.2
39 myopia 10 12.2
40 myopia 14 12.2
41 myopia 20, autosomal dominant 12.2
42 blepharoptosis, myopia, and ectopia lentis 12.2
43 aplasia cutis congenita, high myopia, and cone-rod dysfunction 12.1
44 night blindness, congenital stationary, type 1a 12.1
45 sinus node disease and myopia 12.0
46 ophthalmoplegia, external, and myopia 12.0
47 spondyloepiphyseal dysplasia, myopia, and sensorineural deafness 11.9
48 dandy-walker malformation with mental retardation, macrocephaly, myopia, and brachytelephalangy 11.9
49 epiphyseal dysplasia of femoral head, myopia, and deafness 11.9
50 spinocerebellar degeneration with macular corneal dystrophy, congenital cataracts, and myopia 11.9

Graphical network of the top 20 diseases related to Myopia:



Diseases related to Myopia
Sources

Symptoms & Phenotypes for Myopia

About this section

UMLS symptoms related to Myopia:


aniseikonia

MGI Mouse Phenotypes related to Myopia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.73 CHD7 COL11A1 COL18A1 COL2A1 FBN1 TYR
2 skeleton MP:0005390 9.56 CHD7 COL11A1 COL18A1 COL2A1 FBN1 P3H2
3 hearing/vestibular/ear MP:0005377 9.55 CHD7 COL11A1 COL2A1 SLITRK6 TYR
4 vision/eye MP:0005391 9.1 CHD7 COL18A1 COL2A1 NYX P3H2 TYR
Sources

Drugs & Therapeutics for Myopia

About this section

Drugs for Myopia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 241)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tropicamide Approved, Investigational Phase 4,Phase 2,Not Applicable 1508-75-4 5593
2
Atropine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-55-8, 5908-99-6 174174
3
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
4
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
5
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
6
Loteprednol Approved, Experimental Phase 4 82034-46-6, 129260-79-3 444025 9865442
7
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
8
Levofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 100986-85-4 149096
9
Ofloxacin Approved Phase 4,Phase 1,Phase 2,Not Applicable 82419-36-1 4583
10
Dipivefrin Approved Phase 4,Phase 2,Not Applicable 52365-63-6 3105
11
Povidone Approved Phase 4,Phase 2,Not Applicable 9003-39-8
12
Povidone-iodine Approved Phase 4,Phase 2 25655-41-8
13
Polihexanide Approved, Investigational Phase 4 28757-47-3
14
Hydrogen peroxide Approved, Vet_approved Phase 4,Not Applicable 7722-84-1 784
15
Ketorolac Approved Phase 4,Not Applicable 66635-83-4, 74103-06-3 3826
16
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
17
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
18
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
19
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
20
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 129497-78-5
21
Lactitol Investigational Phase 4,Not Applicable 585-86-4, 585-88-6 493591
22 Mydriatics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
30 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Adjuvants, Anesthesia Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Bronchodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Cathartics Phase 4
37 Gastrointestinal Agents Phase 4,Phase 2,Not Applicable
38 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Cholinesterase Inhibitors Phase 4
40 Laxatives Phase 4
41
Echothiophate Iodide Phase 4 6736-03-4 10547
42 Micronutrients Phase 4,Phase 2,Not Applicable
43 Trace Elements Phase 4,Phase 2,Not Applicable
44 Anti-Infective Agents Phase 4,Phase 1,Phase 2,Not Applicable
45 Ophthalmic Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Nutrients Phase 4,Phase 2,Not Applicable
47 cadexomer iodine Phase 4,Phase 2
48 Carboxymethylcellulose Sodium Phase 4
49 Anti-Infective Agents, Local Phase 4,Phase 2,Not Applicable
50 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 731)
# Name Status NCT ID Phase Drugs
1 Study of Myopia Prevention in Children With Low Concentration of Atropine Unknown status NCT00541177 Phase 4 atropine;tropicamide
2 Echothiophate Iodide for the Prevention of Progression of Myopia Unknown status NCT02544529 Phase 4 Echothiophate Iodide 0.03% Ophthalmic Solution;Carboxymethylcellulose Sodium (0.5%)
3 Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia. Unknown status NCT01917110 Phase 4
4 Comparison of Next Generation Laser Techniques of Myopia Correction: iDesign vs. SMILE Unknown status NCT03001401 Phase 4
5 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
6 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
7 Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study Unknown status NCT02974387 Phase 4 Fluorometholone(FML);Loteprednol (Lotemax)
8 A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK Unknown status NCT01977807 Phase 4
9 Multi Laser Platform Comparison Study for LASIK Unknown status NCT00770094 Phase 4
10 A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK Unknown status NCT02071576 Phase 4
11 A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia Unknown status NCT02112968 Phase 4
12 Effect of Orthokeratology Versus Spectacles on Myopia Progression in Chinese Children: A Crossover Trial Completed NCT02186184 Phase 4
13 Visual Outcomes and Contrast Sensitivity After Myopic LASIK Completed NCT01746589 Phase 4
14 Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds Completed NCT00564213 Phase 4 PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds
15 A Comparison of PRK and LASIK for Correction of Myopia Completed NCT00404105 Phase 4
16 An Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients Completed NCT01173198 Phase 4
17 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
18 SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Completed NCT03409250 Phase 4 Ranibizumab, Lucentis
19 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Completed NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
20 Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes Completed NCT01387360 Phase 4
21 Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction Completed NCT01225952 Phase 4
22 Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap Completed NCT01693939 Phase 4
23 The Effects of Low Dose Atropine on Choroidal Thickness Completed NCT03544827 Phase 4 Atropine;Atropine
24 The Influence of Atropine on Choroidal Thickness Completed NCT03158142 Phase 4 Atropine Sulfate 1% Oph Soln
25 Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK Completed NCT00821236 Phase 4
26 Clinical Study of Approved Contact Lenses Completed NCT03351101 Phase 4
27 BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study Completed NCT02537730 Phase 4
28 Clinical Evaluation of Daily Disposable Contact Lenses Completed NCT02097030 Phase 4
29 Daily Disposable Comparison Study Completed NCT02094677 Phase 4
30 Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist Completed NCT02024698 Phase 4
31 Evaluation of Stenfilcon A Versus Etafilcon A Completed NCT01809834 Phase 4
32 Clinical Performance of Stenfilcon A Versus Filcon II 3 Completed NCT01808209 Phase 4
33 Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses Completed NCT01707238 Phase 4
34 Evaluation of Comfilcon A and Senofilcon A Lenses Completed NCT01695369 Phase 4
35 Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK Completed NCT00889941 Phase 4
36 Comparative Performance of PureVision, Acuvue Oasys and O2Optix Completed NCT00640341 Phase 4
37 Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision Completed NCT00627302 Phase 4 PEG-400;Systane
38 Long-term Effects of Laser Refractive Surgery Completed NCT00350246 Phase 4
39 Effects of Contact Lens Care Regimens on the Corneal Epithelium Completed NCT00349882 Phase 4 Marketed multipurpose disinfection regimen
40 Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort Completed NCT00349843 Phase 4 Marketed soft lens multipurpose disinfection regimen
41 Daily Wear Corneal Infiltrative Event Study Completed NCT00937105 Phase 4
42 Visual Performance After RESTOR Implantation Completed NCT01065064 Phase 4
43 The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers Completed NCT03585790 Phase 4
44 Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface Completed NCT01250925 Phase 4 ReNu MultiPlus® MultiPurpose Solution;OPTI-FREE® RepleniSH®;Clear Care®
45 Corneal and Conjunctival Sensitivity and Staining Study Completed NCT00455455 Phase 4 Optifree RepleniSH Multipurpose Disinfecting Solution;ReNu Multiplus Multipurpose Solution
46 Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK Completed NCT00347204 Phase 4 ketorolac (Acular LS);Nepafenac (Nevanac)
47 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
48 Evaluation of 3 Intraocular Lenses Following Lens Extraction Completed NCT01122576 Phase 4
49 Efficacy and Safety of Adding Atracurium to Percaruncular Block for High Myopes Undergoing Cataract Surgery Completed NCT03243500 Phase 4 Atracurium;Lidocaine 2%;Bupivacaine 0.5%;hyaluronidase powder
50 Clinical Evaluation of the One-Piece Tecnis Multifocal Intraocular Lens (IOL) Completed NCT01210807 Phase 4

Search NIH Clinical Center for Myopia

Cochrane evidence based reviews: myopia

Sources

Genetic Tests for Myopia

About this section

Genetic tests related to Myopia:

# Genetic test Affiliating Genes
1 Myopia 30
Sources

Anatomical Context for Myopia

About this section

MalaCards organs/tissues related to Myopia:

42
Eye, Retina, Testes, Endothelial, Brain, Bone, Heart
Sources

Publications for Myopia

About this section

Articles related to Myopia:

(show top 50) (show all 3366)
# Title Authors Year
1
Corrigendum to "Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression" [EBioMedicine 28 (2018) 274-286]. ( 30885727 )
2019
2
Interocular Symmetry of Fixation, Optic Disc, and Corneal Astigmatism in Bilateral High Myopia: The Shanghai High Myopia Study. ( 30783557 )
2019
3
Correction of Myopia and Myopic Astigmatism by Implantation of a Phakic Posterior Chamber Implantable Collamer Lens. ( 30913890 )
2019
4
Analysis of Corneal Spherical Aberrations in Cataract Patients with High Myopia. ( 30723220 )
2019
5
Dome-shaped macula: a potential protective factor for visual acuity after cataract surgery in patients with high myopia. ( 30602448 )
2019
6
Near vision in individuals with Down syndrome: a vision screening study. ( 30914784 )
2019
7
Magnetic resonance imaging findings of age-related distance esotropia in Japanese patients with high myopia. ( 30671656 )
2019
8
Significant hyperopic shift in a patient with extreme myopia following severe hypotonia caused by glaucoma filtering surgery. ( 30175614 )
2019
9
Uveal effusion and transient myopia as the initial presentation of systemic lupus erythematosus patient with pulmonary arterial hypertension: case report. ( 30791856 )
2019
10
Five-year results of small incision lenticule extraction (SMILE) and femtosecond laser LASIK (FS-LASIK) for myopia. ( 30632671 )
2019
11
15-Month Visual Outcomes and Corneal Power Changes of SMILE in Treating High Myopia With Maximum Myopic Meridian Exceeding 10.00 D. ( 30633785 )
2019
12
Evaluation of Different IOL Calculation Formulas of the ASCRS Calculator in Eyes After Corneal Refractive Laser Surgery for Myopia With Multifocal IOL Implantation. ( 30633788 )
2019
13
Imaging in myopia: potential biomarkers, current challenges and future developments. ( 30636210 )
2019
14
Longitudinal Changes in Spherical Equivalent Refractive Error Among Children With Preschool Myopia. ( 30640967 )
2019
15
Comparison of the posterior corneal elevation and biomechanics after SMILE and LASEK for myopia: a short- and long-term observation. ( 30643965 )
2019
16
Long-term safety of posterior chamber implantable phakic contact lens for the correction of myopia. ( 30662257 )
2019
17
Genome-wide DNA hypermethylation and homocysteine increase a risk for myopia. ( 30662838 )
2019
18
Evaluation of spectral domain optical coherence tomography parameters in discriminating preperimetric glaucoma from high myopia. ( 30662841 )
2019
19
Differential expression of connective tissue growth factor and hepatocyte growth factor in the vitreous of patients with high myopia versus vitreomacular interface disease. ( 30665391 )
2019
20
Oral crocetin administration suppressed refractive shift and axial elongation in a murine model of lens-induced myopia. ( 30670743 )
2019
21
HOXA9 is a novel myopia risk gene. ( 30674274 )
2019
22
Prevalence and risk factors of myopia in adult Korean population: Korea national health and nutrition examination survey 2013-2014 (KNHANES VI). ( 30677087 )
2019
23
Little effect of 0.01% atropine eye drops as used in myopia prevention on the pattern electroretinogram. ( 30680489 )
2019
24
CPSF1 mutations are associated with early-onset high myopia and involved in retinal ganglion cell axon projection. ( 30689892 )
2019
25
Myopia is associated with education: Results from NHANES 1999-2008. ( 30695049 )
2019
26
Alpha2 -adrenoceptor agonists inhibit form-deprivation myopia in the chick. ( 30699466 )
2019
27
Exome genotyping and linkage analysis identifies two novel linked regions and replicates two others for myopia in Ashkenazi Jewish families. ( 30704416 )
2019
28
Prevention and Management of Myopia and Myopic Pathology. ( 30707221 )
2019
29
Long-term (5 years) follow-up of small-incision lenticule extraction in mild-to-moderate myopia. ( 30709628 )
2019
30
A Genome-Wide Association Study for Susceptibility to Visual Experience-Induced Myopia. ( 30721303 )
2019
31
2020 vision or myopia? A personal perspective on the future of cancer imaging and an introduction to the sequels to the "How I Read Series". ( 30728071 )
2019
32
Rectus Extraocular Muscle Paths and Staphylomata in High Myopia. ( 30731081 )
2019
33
Comparison of visual quality after EVO-ICL implantation and SMILE to select the appropriate surgical method for high myopia. ( 30732575 )
2019
34
Transepithelial photorefractive intrastromal corneal crosslinking versus photorefractive keratectomy in low myopia. ( 30733107 )
2019
35
Inducement and Evaluation of a Murine Model of Experimental Myopia. ( 30735205 )
2019
36
Microdistortions in Bowman's Layer 3 Years After SMILE for Myopia. ( 30742223 )
2019
37
Risk factors associated with myopia in schoolchildren in Ireland. ( 30745305 )
2019
38
Retardation of Myopia Progression by Multifocal Soft Contact Lenses. ( 30745799 )
2019
39
Different Disc Characteristics Associated With High Myopia and the Location of Glaucomatous Damage in Primary Open-Angle Glaucoma and Normal-Tension Glaucoma. ( 30789526 )
2019
40
Cilioretinal Arteries and Cilioretinal Veins in Eyes with Pathologic Myopia. ( 30792400 )
2019
41
Prevalence of Myopia and Associated Risk Factors in Schoolchildren in North India. ( 30801501 )
2019
42
The Influence of Overnight Orthokeratology on Ocular Surface and Meibomian Gland Dysfunction in Teenagers with Myopia. ( 30805209 )
2019
43
Modified Posterior Scleral Reinforcement as a Treatment for High Myopia in Children and Its Therapeutic Effect. ( 30805365 )
2019
44
Visual performance after implantation of two types of phakic foldable intraocular lenses for correction of high myopia. ( 30809486 )
2019
45
Myopia - A 21st Century Public Health Issue. ( 30817824 )
2019
46
IMI - Myopia Control Reports Overview and Introduction. ( 30817825 )
2019
47
IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. ( 30817826 )
2019
48
IMI - Report on Experimental Models of Emmetropization and Myopia. ( 30817827 )
2019
49
IMI - Myopia Genetics Report. ( 30817828 )
2019
50
IMI - Interventions Myopia Institute: Interventions for Controlling Myopia Onset and Progression Report. ( 30817829 )
2019
Sources

Variations for Myopia

About this section

ClinVar genetic disease variations for Myopia:

6 (show top 50) (show all 52)
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh37 Chromosome 11, 47433573: 47433573
2 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh38 Chromosome 11, 47412022: 47412022
3 TYR NM_000372.4(TYR): c.1A> G (p.Met1Val) single nucleotide variant Pathogenic rs28940881 GRCh37 Chromosome 11, 88911122: 88911122
4 TYR NM_000372.4(TYR): c.1A> G (p.Met1Val) single nucleotide variant Pathogenic rs28940881 GRCh38 Chromosome 11, 89177954: 89177954
5 COL2A1 NM_033150.2(COL2A1): c.2503C> T (p.Arg835Cys) single nucleotide variant Pathogenic rs121912882 GRCh37 Chromosome 12, 48373317: 48373317
6 COL2A1 NM_033150.2(COL2A1): c.2503C> T (p.Arg835Cys) single nucleotide variant Pathogenic rs121912882 GRCh38 Chromosome 12, 47979534: 47979534
7 SLC25A4 NM_001151.3(SLC25A4): c.368C> A (p.Ala123Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912683 GRCh37 Chromosome 4, 186066174: 186066174
8 SLC25A4 NM_001151.3(SLC25A4): c.368C> A (p.Ala123Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912683 GRCh38 Chromosome 4, 185145020: 185145020
9 TYR NM_000372.4(TYR): c.1037-7T> A single nucleotide variant Pathogenic/Likely pathogenic rs61754381 GRCh37 Chromosome 11, 88960984: 88960984
10 TYR NM_000372.4(TYR): c.1037-7T> A single nucleotide variant Pathogenic/Likely pathogenic rs61754381 GRCh38 Chromosome 11, 89227816: 89227816
11 COL4A4 NM_000092.4(COL4A4): c.2320G> C (p.Gly774Arg) single nucleotide variant Likely pathogenic rs569681869 GRCh37 Chromosome 2, 227924184: 227924184
12 COL4A4 NM_000092.4(COL4A4): c.2320G> C (p.Gly774Arg) single nucleotide variant Likely pathogenic rs569681869 GRCh38 Chromosome 2, 227059468: 227059468
13 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh37 Chromosome 12, 123001951: 123001951
14 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh38 Chromosome 12, 122517404: 122517404
15 46;X;t(X;9)(p22.2;p13)dn Translocation Uncertain significance
16 46;XY;t(2;14)(p23;q13)dn Translocation Uncertain significance
17 46;XY;t(5;15)(q11.2;q24) Translocation Pathogenic
18 ZNF469 NM_001127464.2(ZNF469): c.470G> A (p.Gly157Glu) single nucleotide variant Uncertain significance rs781096189 GRCh38 Chromosome 16, 88427940: 88427940
19 ZNF469 NM_001127464.2(ZNF469): c.470G> A (p.Gly157Glu) single nucleotide variant Uncertain significance rs781096189 GRCh37 Chromosome 16, 88494348: 88494348
20 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh37 Chromosome MT, 3275: 3275
21 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh38 Chromosome MT, 3275: 3275
22 POGZ NM_015100.3(POGZ): c.402_409dupTGCCAATC (p.His137Leufs) duplication Likely pathogenic rs1057518799 GRCh38 Chromosome 1, 151430716: 151430723
23 POGZ NM_015100.3(POGZ): c.402_409dupTGCCAATC (p.His137Leufs) duplication Likely pathogenic rs1057518799 GRCh37 Chromosome 1, 151403192: 151403199
24 CHD7 NM_017780.3(CHD7): c.6892C> T (p.Gln2298Ter) single nucleotide variant Pathogenic rs1057518891 GRCh37 Chromosome 8, 61767038: 61767038
25 CHD7 NM_017780.3(CHD7): c.6892C> T (p.Gln2298Ter) single nucleotide variant Pathogenic rs1057518891 GRCh38 Chromosome 8, 60854479: 60854479
26 FBN1 NM_000138.4(FBN1): c.6800A> T (p.Asn2267Ile) single nucleotide variant Pathogenic rs1057518812 GRCh38 Chromosome 15, 48430742: 48430742
27 FBN1 NM_000138.4(FBN1): c.6800A> T (p.Asn2267Ile) single nucleotide variant Pathogenic rs1057518812 GRCh37 Chromosome 15, 48722939: 48722939
28 FBN1 NM_000138.4(FBN1): c.1481G> T (p.Cys494Phe) single nucleotide variant Likely pathogenic rs1057518881 GRCh37 Chromosome 15, 48805853: 48805853
29 FBN1 NM_000138.4(FBN1): c.1481G> T (p.Cys494Phe) single nucleotide variant Likely pathogenic rs1057518881 GRCh38 Chromosome 15, 48513656: 48513656
30 FBN1 NM_000138.4(FBN1): c.840_843delTGAA (p.Asn280Lysfs) deletion Pathogenic rs1057518909 GRCh37 Chromosome 15, 48826296: 48826299
31 FBN1 NM_000138.4(FBN1): c.840_843delTGAA (p.Asn280Lysfs) deletion Pathogenic rs1057518909 GRCh38 Chromosome 15, 48534099: 48534102
32 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh38 Chromosome 16, 15724166: 15724166
33 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh37 Chromosome 16, 15818023: 15818023
34 EP300 NM_001429.3(EP300): c.2053+4A> T single nucleotide variant Uncertain significance rs1057518889 GRCh37 Chromosome 22, 41537230: 41537230
35 EP300 NM_001429.3(EP300): c.2053+4A> T single nucleotide variant Uncertain significance rs1057518889 GRCh38 Chromosome 22, 41141226: 41141226
36 AFF2 NM_002025.3(AFF2): c.3209A> G (p.His1070Arg) single nucleotide variant Uncertain significance rs1057518785 GRCh37 Chromosome X, 148049164: 148049164
37 AFF2 NM_002025.3(AFF2): c.3209A> G (p.His1070Arg) single nucleotide variant Uncertain significance rs1057518785 GRCh38 Chromosome X, 148967634: 148967634
38 CACNA1F NM_005183.3(CACNA1F): c.694A> T (p.Lys232Ter) single nucleotide variant Likely pathogenic rs1057518829 GRCh37 Chromosome X, 49086805: 49086805
39 CACNA1F NM_005183.3(CACNA1F): c.694A> T (p.Lys232Ter) single nucleotide variant Likely pathogenic rs1057518829 GRCh38 Chromosome X, 49230343: 49230343
40 COL11A1 NM_080629.2(COL11A1): c.4084_4101delTCTGGTGAGGCTGGCCCA (p.Ser1362_Pro1367del) deletion Likely pathogenic rs1553200431 GRCh37 Chromosome 1, 103377736: 103377753
41 COL11A1 NM_080629.2(COL11A1): c.4084_4101delTCTGGTGAGGCTGGCCCA (p.Ser1362_Pro1367del) deletion Likely pathogenic rs1553200431 GRCh38 Chromosome 1, 102912180: 102912197
42 COL4A4 NM_000092.4(COL4A4): c.4394G> A (p.Gly1465Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs533297350 GRCh38 Chromosome 2, 227010441: 227010441
43 COL4A4 NM_000092.4(COL4A4): c.4394G> A (p.Gly1465Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs533297350 GRCh37 Chromosome 2, 227875157: 227875157
44 TNC NM_002160.3(TNC): c.890A> G (p.Asn297Ser) single nucleotide variant Uncertain significance rs1554717312 GRCh37 Chromosome 9, 117849120: 117849120
45 TNC NM_002160.3(TNC): c.890A> G (p.Asn297Ser) single nucleotide variant Uncertain significance rs1554717312 GRCh38 Chromosome 9, 115086841: 115086841
46 ZNF469 NM_001127464.2(ZNF469): c.2569A> G (p.Asn857Asp) single nucleotide variant Uncertain significance rs1555518955 GRCh37 Chromosome 16, 88496447: 88496447
47 ZNF469 NM_001127464.2(ZNF469): c.2569A> G (p.Asn857Asp) single nucleotide variant Uncertain significance rs1555518955 GRCh38 Chromosome 16, 88430039: 88430039
48 ZNF469 NM_001127464.2(ZNF469): c.9448G> A (p.Gly3150Ser) single nucleotide variant Uncertain significance rs887755283 GRCh38 Chromosome 16, 88437002: 88437002
49 ZNF469 NM_001127464.2(ZNF469): c.9448G> A (p.Gly3150Ser) single nucleotide variant Uncertain significance rs887755283 GRCh37 Chromosome 16, 88503410: 88503410
50 subset of 22 genes:FLCN; RAI1 GRCh37/hg19 17p11.2(chr17: 16936603-18184130) copy number loss Pathogenic GRCh37 Chromosome 17, 16936603: 18184130
Sources

Expression for Myopia

About this section
Search GEO for disease gene expression data for Myopia.
Sources

Pathways for Myopia

About this section

Pathways related to Myopia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Degradation of the extracellular matrix 67
Show member pathways
 11.67 COL11A1 COL18A1 COL2A1 FBN1 P3H2
2
ECM-receptor interaction 38
Show member pathways
 11.31 COL18A1 COL2A1 FBN1
Sources

GO Terms for Myopia

About this section

Cellular components related to Myopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.62 COL11A1 COL18A1 COL2A1 FBN1
2 extracellular matrix GO:0031012 9.55 COL11A1 COL18A1 COL2A1 FBN1 NYX
3 collagen trimer GO:0005581 9.43 COL11A1 COL18A1 COL2A1
4 endoplasmic reticulum lumen GO:0005788 9.35 COL11A1 COL18A1 COL2A1 FBN1 P3H2
5 basement membrane GO:0005604 8.92 COL18A1 COL2A1 FBN1 P3H2

Biological processes related to Myopia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.67 COL11A1 COL18A1 COL2A1 FBN1
2 skeletal system development GO:0001501 9.65 CHD7 COL2A1 FBN1
3 camera-type eye development GO:0043010 9.58 CHD7 FBN1 SLITRK6
4 eye development GO:0001654 9.49 SCO2 SLC39A5
5 innervation GO:0060384 9.46 CHD7 SLITRK6
6 sensory perception of sound GO:0007605 9.46 CHD7 COL11A1 COL2A1 SLITRK6
7 cartilage condensation GO:0001502 9.43 COL11A1 COL2A1
8 heart morphogenesis GO:0003007 9.43 CHD7 COL11A1 COL2A1
9 proteoglycan metabolic process GO:0006029 9.32 COL11A1 COL2A1
10 inner ear morphogenesis GO:0042472 9.26 CHD7 COL11A1 COL2A1 SLITRK6
11 visual perception GO:0007601 9.1 COL11A1 COL18A1 COL2A1 NYX SLITRK6 TYR

Molecular functions related to Myopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.33 COL11A1 FBN1 LRPAP1
2 extracellular matrix structural constituent conferring tensile strength GO:0030020 9.13 COL11A1 COL18A1 COL2A1
3 extracellular matrix structural constituent GO:0005201 8.92 COL11A1 COL18A1 COL2A1 FBN1
Sources

Sources for Myopia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....